Robert N. Freedman

Jan 9, 2025 | jdsupra.com | Robert N. Freedman |Ryan Mitteness |Amanda Rose

The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable. Fenwick’s Amanda Rose, Rob Freedman, and Ryan Mitteness recently unpacked these developments—and what innovators can do to prepare to go public in 2025—alongside Morgan Stanley’s Ryuk Byun and Tedd Smith. Here are the essential insights for life sciences companies considering going public in 2025.

Jan 6, 2025 | jdsupra.com | Chelsea Anderson |Robert N. Freedman |Ryan Mitteness

This article is part of our series on clinical data considerations. Read How to Prepare for Disclosure. For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword. Disclosures can position your company favorably for investors, or it can invite serious regulatory scrutiny that delays your plans.

May 18, 2023 | jdsupra.com | Aaron Dunlap |Robert N. Freedman |Kari Hebrank

May 22nd, 2023 12:00 PM - 1:30 PM EDT On May 8, 2023, Gov. Ron DeSantis signed into law Senate Bill 264, creating Florida Statutes sections 692.201 through 692.205, which prohibits the direct or indirect ownership of various categories of real estate by individuals and companies (in addition to government and party officials) from a number of foreign nations.

May 16, 2023 | jdsupra.com | Aaron Dunlap |Robert N. Freedman |Kari Hebrank

May 16, 2023 Aaron Dunlap, Robert Freedman, Kari Hebrank, Jin Liu, William Sklar Carlton Fields + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: On May 8, 2023, Gov.

Mar 10, 2023 | jdsupra.com | Ran Ben-Tzur |Robert N. Freedman |Ron Llewellyn

After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their cash runway, considering strategic options and, in certain cases, taking steps to prepare for a potential public debut when the markets improve. Please see full Publication below for more information.  Download PDF